BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Beloqui A, Alhouayek M, Carradori D, Vanvarenberg K, Muccioli GG, Cani PD, Préat V. A Mechanistic Study on Nanoparticle-Mediated Glucagon-Like Peptide-1 (GLP-1) Secretion from Enteroendocrine L Cells. Mol Pharmaceutics 2016;13:4222-30. [DOI: 10.1021/acs.molpharmaceut.6b00871] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang Y, Wang Y, Li X, Nie D, Liu C, Gan Y. Ligand-modified nanocarriers for oral drug delivery: Challenges, rational design, and applications. J Control Release 2022;352:813-32. [PMID: 36368493 DOI: 10.1016/j.jconrel.2022.11.010] [Reference Citation Analysis]
2 Mwema A, Bottemanne P, Paquot A, Ucakar B, Vanvarenberg K, Alhouayek M, Muccioli GG, des Rieux A. Lipid nanocapsules for the nose-to-brain delivery of the anti-inflammatory bioactive lipid PGD(2)-G. Nanomedicine 2022;48:102633. [PMID: 36435364 DOI: 10.1016/j.nano.2022.102633] [Reference Citation Analysis]
3 Ibnat N, Zaman R, Uddin MB, Chowdhury E, Lee CY. Improved systemic half-life of glucagon-like peptide-1-loaded carbonate apatite nanoparticles in rats. World J Diabetes 2022; 13(8): 613-621 [DOI: 10.4239/wjd.v13.i8.613] [Reference Citation Analysis]
4 An Y, Li Y, Bian N, Ding X, Chang X, Liu J, Wang G. Different Interactive Effects of Metformin and Acarbose With Dietary Macronutrient Intakes on Patients With Type 2 Diabetes Mellitus: Novel Findings From the MARCH Randomized Trial in China. Front Nutr 2022;9:861750. [PMID: 35558742 DOI: 10.3389/fnut.2022.861750] [Reference Citation Analysis]
5 Lok KH, Wareham NJ, Nair RS, How CW, Chuah LH. Revisiting The Concept of Incretin and Enteroendocrine L-cells as Type 2 Diabetes Mellitus Treatment. Pharmacol Res 2022;:106237. [PMID: 35487405 DOI: 10.1016/j.phrs.2022.106237] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Qin W, Ying W, Hamaker B, Zhang G. Slow digestion-oriented dietary strategy to sustain the secretion of GLP-1 for improved glucose homeostasis. Compr Rev Food Sci Food Saf 2021. [PMID: 34350681 DOI: 10.1111/1541-4337.12808] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
7 Eissa NG, Elsabahy M, Allam A. Engineering of smart nanoconstructs for delivery of glucagon-like peptide-1 analogs. Int J Pharm 2021;597:120317. [PMID: 33540005 DOI: 10.1016/j.ijpharm.2021.120317] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
8 Pinyo J, Hara H, Hira T. Diet-induced obesity enhances postprandial glucagon-like peptide-1 secretion in Wistar rats, but not in diabetic Goto-Kakizaki rats. Br J Nutr 2021;126:518-30. [PMID: 33143769 DOI: 10.1017/S000711452000433X] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
9 Xu Y, De Keersmaecker H, Braeckmans K, De Smedt S, Cani PD, Préat V, Beloqui A. Targeted nanoparticles towards increased L cell stimulation as a strategy to improve oral peptide delivery in incretin-based diabetes treatment. Biomaterials 2020;255:120209. [PMID: 32580098 DOI: 10.1016/j.biomaterials.2020.120209] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
10 Xu Y, Shrestha N, Préat V, Beloqui A. Overcoming the intestinal barrier: A look into targeting approaches for improved oral drug delivery systems. Journal of Controlled Release 2020;322:486-508. [DOI: 10.1016/j.jconrel.2020.04.006] [Cited by in Crossref: 62] [Cited by in F6Publishing: 69] [Article Influence: 20.7] [Reference Citation Analysis]
11 Paton CM, Son Y, Vaughan RA, Cooper JA. Free Fatty Acid-Induced Peptide YY Expression Is Dependent on TG Synthesis Rate and Xbp1 Splicing. Int J Mol Sci 2020;21:E3368. [PMID: 32397573 DOI: 10.3390/ijms21093368] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
12 Xu Y, Van Hul M, Suriano F, Préat V, Cani PD, Beloqui A. Novel strategy for oral peptide delivery in incretin-based diabetes treatment. Gut 2020;69:911-9. [PMID: 31401561 DOI: 10.1136/gutjnl-2019-319146] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 8.7] [Reference Citation Analysis]
13 Taneja G, Sud A, Pendse N, Panigrahi B, Kumar A, Sharma AK. Nano-medicine and Vascular Endothelial Dysfunction: Options and Delivery Strategies. Cardiovasc Toxicol 2019;19:1-12. [DOI: 10.1007/s12012-018-9491-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
14 Kondrashina A, Seratlic S, Kandil D, Treguier N, Kilcawley K, Schellekens H, Beresford T, Giblin L. Irish Cheddar cheese increases glucagon-like peptide-1 secretion in vitro but bioactivity is lost during gut transit. Food Chemistry 2018;265:9-17. [DOI: 10.1016/j.foodchem.2018.05.062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
15 Shrestha N, Bouttefeux O, Vanvarenberg K, Lundquist P, Cunarro J, Tovar S, Khodus G, Andersson E, Keita ÅV, Gonzalez Dieguez C, Artursson P, Préat V, Beloqui A. The stimulation of GLP-1 secretion and delivery of GLP-1 agonists via nanostructured lipid carriers. Nanoscale 2018;10:603-13. [DOI: 10.1039/c7nr07736j] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
16 Xu Y, Carradori D, Alhouayek M, Muccioli GG, Cani PD, Préat V, Beloqui A. Size Effect on Lipid Nanocapsule-Mediated GLP-1 Secretion from Enteroendocrine L Cells. Mol Pharmaceutics 2018;15:108-15. [DOI: 10.1021/acs.molpharmaceut.7b00742] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.8] [Reference Citation Analysis]
17 Beloqui A, del Pozo-rodríguez A, Isla A, Rodríguez-gascón A, Solinís MÁ. Nanostructured lipid carriers as oral delivery systems for poorly soluble drugs. Journal of Drug Delivery Science and Technology 2017;42:144-54. [DOI: 10.1016/j.jddst.2017.06.013] [Cited by in Crossref: 43] [Cited by in F6Publishing: 43] [Article Influence: 7.2] [Reference Citation Analysis]
18 Singh SK, Singh S, Lillard JW Jr, Singh R. Drug delivery approaches for breast cancer. Int J Nanomedicine 2017;12:6205-18. [PMID: 28883730 DOI: 10.2147/IJN.S140325] [Cited by in Crossref: 101] [Cited by in F6Publishing: 107] [Article Influence: 16.8] [Reference Citation Analysis]